ES2053208T3 - Metodo para prevenir o limitar el daño por reperfusion. - Google Patents

Metodo para prevenir o limitar el daño por reperfusion.

Info

Publication number
ES2053208T3
ES2053208T3 ES90917677T ES90917677T ES2053208T3 ES 2053208 T3 ES2053208 T3 ES 2053208T3 ES 90917677 T ES90917677 T ES 90917677T ES 90917677 T ES90917677 T ES 90917677T ES 2053208 T3 ES2053208 T3 ES 2053208T3
Authority
ES
Spain
Prior art keywords
reperfusion
prevent
compound
limit damage
piperazineacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917677T
Other languages
English (en)
Inventor
Belle Herman Van
Laerhoven Willy J C Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2053208T3 publication Critical patent/ES2053208T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Abstract

EL USO DE UNA N-ALQUILPIPERAZINAALCANAMIDA PARA PREVENIR Y/O LIMITAR DAÑOS DE REPERFUSION TRAS LA REPERFUSION DE UN ORGANO O TEJIDO MUSCULAR, SOBRE TODO EN UN PACIENTE QUE SUFRE UNA TROMBOLISIS O REPERFUSION DEL CORAZON DESPUES DE UNA OPERACION A CORAZON ABIERTO O DESPUES DE HABERSELE TRANSPLANTADO EL CORAZON. EL USO DE UNA N-ALQUILPIPERAZINAALCENAMIDA PARA PREVENIR Y/O LIMITAR EL DAÑO DE REPERFUSION TRAS LA REPERFUSION DE UN CORAZON TRANSPLANTADO. EL USO DE UNA N-ALQUILPIPERAZINAALCANAMIDA PARA GUARDAR UN CORAZON QUE VA A SER TRANSPLANTADO DURANTE 24 HORAS POR LO MENOS EN UNA DISOLUCION CARDIOPLEGICA. COMPUESTOS QUE CONTIENEN UNA CANTIDAD EFICAZ PARA PREVENIR Y/O LIMITAR EL DAÑO DE REPERFUSION DE UN DERIVADO DE N-ARIL-PIPERAZINAACANAMIDA Y QUE OPCIONALMENTE CONTIENE ADEMAS UN AGENTE TROMBOLITICO Y/O CICLODEXTRINA O UN ETER DERIVADO DE LA MISMA. PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS. NUEVOS COMPUESTOS DE N-ALQUILPIPERAZINAALCANAMIDA Y UN PROCESO PARA LA PREPARACION DE DICHOS COMPUESTOS.
ES90917677T 1989-11-22 1990-11-19 Metodo para prevenir o limitar el daño por reperfusion. Expired - Lifetime ES2053208T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44014289A 1989-11-22 1989-11-22
SG118494A SG118494G (en) 1989-11-22 1994-08-20 Method of preventing or limiting reperfusion damage

Publications (1)

Publication Number Publication Date
ES2053208T3 true ES2053208T3 (es) 1994-07-16

Family

ID=26664237

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90917677T Expired - Lifetime ES2053208T3 (es) 1989-11-22 1990-11-19 Metodo para prevenir o limitar el daño por reperfusion.
ES93201656T Expired - Lifetime ES2173883T3 (es) 1989-11-22 1990-11-19 Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES93201656T Expired - Lifetime ES2173883T3 (es) 1989-11-22 1990-11-19 Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.

Country Status (22)

Country Link
EP (2) EP0455789B1 (es)
JP (1) JP2574585B2 (es)
KR (1) KR0165686B1 (es)
AT (2) ATE102831T1 (es)
AU (1) AU632888B2 (es)
CA (1) CA2044143C (es)
CY (1) CY1869A (es)
DE (2) DE69007471T2 (es)
DK (2) DK0577171T3 (es)
ES (2) ES2053208T3 (es)
FI (1) FI109694B (es)
HK (1) HK115095A (es)
HU (1) HU215847B (es)
IE (1) IE65121B1 (es)
IL (1) IL96390A (es)
NO (2) NO304519B1 (es)
NZ (1) NZ236168A (es)
PT (2) PT95959B (es)
RU (1) RU2093156C1 (es)
SG (1) SG118494G (es)
WO (1) WO1991007967A2 (es)
ZA (1) ZA909345B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
ES2319876T3 (es) 2001-05-18 2009-05-14 Astrazeneca Ab Derivados de 4 (fenil-piperazinil-metil) benzamida y su uso para el tratamiento de la ansiedad o trastornos gastrointestinales.
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
CA2575975A1 (en) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
KR101900124B1 (ko) 2014-06-25 2018-09-18 전남대학교산학협력단 전복 박리용 조성물
KR101644299B1 (ko) 2014-07-22 2016-08-02 주식회사 엔바이로젠 오미자 및 삼채 추출물을 유효성분으로 포함하는 전복 박리용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
FI109694B (fi) 2002-09-30
DK0577171T3 (da) 2002-06-03
HUT58709A (en) 1992-03-30
HU215847B (hu) 1999-04-28
ES2173883T3 (es) 2002-11-01
PT102145B (pt) 2002-06-28
RU2093156C1 (ru) 1997-10-20
KR920700644A (ko) 1992-08-10
ZA909345B (en) 1992-08-26
DE69007471D1 (de) 1994-04-21
EP0455789B1 (en) 1994-03-16
KR0165686B1 (ko) 1999-01-15
IE65121B1 (en) 1995-10-04
PT95959B (pt) 1998-08-31
WO1991007967A2 (en) 1991-06-13
CA2044143A1 (en) 1991-05-23
NZ236168A (en) 1993-05-26
NO982078D0 (no) 1998-05-07
EP0577171A3 (en) 1994-06-29
EP0577171B1 (en) 2002-03-06
IL96390A (en) 1995-06-29
NO912511D0 (no) 1991-06-26
CY1869A (en) 1996-04-05
PT102145A (pt) 1999-10-29
FI913433A0 (fi) 1991-07-16
DK0455789T3 (da) 1994-04-05
NO311701B1 (no) 2002-01-14
EP0577171A2 (en) 1994-01-05
IE904209A1 (en) 1991-05-22
ATE213943T1 (de) 2002-03-15
NO304519B1 (no) 1999-01-04
AU632888B2 (en) 1993-01-14
NO982078L (no) 1991-08-26
DE69033926T2 (de) 2002-10-24
AU6876391A (en) 1991-06-26
CA2044143C (en) 2002-11-19
NO912511L (no) 1991-08-26
ATE102831T1 (de) 1994-04-15
DE69007471T2 (de) 1994-06-23
PT95959A (pt) 1991-09-13
HU9102436D0 (en) 1991-12-30
JP2574585B2 (ja) 1997-01-22
SG118494G (en) 1994-11-25
IL96390A0 (en) 1991-08-16
DE69033926D1 (de) 2002-04-11
EP0455789A1 (en) 1991-11-13
WO1991007967A3 (en) 1991-07-11
HK115095A (en) 1995-07-21

Similar Documents

Publication Publication Date Title
ES2053208T3 (es) Metodo para prevenir o limitar el daño por reperfusion.
PT96145A (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
FI850078L (fi) N-(4-piperidinyl)-bicykliska -kondenserade 2-imidazolaminderivat.
NO932745L (no) Triazolyltiometyltiocefalosporinhydroklorid, dets krystalliske hydrat samt fremgangsmaate for fremstilling
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
BR9305164A (pt) Composto, formulação farmacêutica e processo para preparar um composto
FI933719A0 (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 455789

Country of ref document: ES